The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Paul D. Miller

Colorado Center for Bone Research

Lakewood

USA

[email]@aol.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Colorado Center for Bone Research, Lakewood, USA. 2012
  • Colorado Center for Bone Research, 3190 South Wadsworth Blvd, Lakewood, CO 80227, USA. 2004 - 2010
  • Department of Medicine, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Denver, USA. 1999 - 2009
  • University of Colorado Health Sciences Center, Lakewood, USA. 2003
  • The Scientific Advisory Board of the Bone Measurement Institute. 1998

References

  1. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Miller, P.D., Recker, R.R., Reginster, J.Y., Riis, B.J., Czerwinski, E., Masanauskaite, D., Kenwright, A., Lorenc, R., Stakkestad, J.A., Lakatos, P. Osteoporos. Int (2012) [Pubmed]
  2. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Miller, P.D., Derman, R.J. Osteoporos. Int (2010) [Pubmed]
  3. Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. Miller, P.D., Delmas, P.D., Huss, H., Patel, K.M., Schimmer, R.C., Adami, S., Recker, R.R. Calcif. Tissue Int. (2010) [Pubmed]
  4. Denosumab: anti-RANKL antibody. Miller, P.D. Curr. Osteoporos. Rep (2009) [Pubmed]
  5. Diagnosis and treatment of osteoporosis in chronic renal disease. Miller, P.D. Semin. Nephrol. (2009) [Pubmed]
  6. Fragility fractures in chronic kidney disease: an opinion-based approach. Miller, P.D. Cleve. Clin. J. Med (2009) [Pubmed]
  7. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Miller, P.D., Bolognese, M.A., Lewiecki, E.M., McClung, M.R., Ding, B., Austin, M., Liu, Y., San Martin, J. Bone (2008) [Pubmed]
  8. Safety of parathyroid hormone for the treatment of osteoporosis. Miller, P.D. Curr. Osteoporos. Rep (2008) [Pubmed]
  9. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Miller, P.D., Epstein, S., Sedarati, F., Reginster, J.Y. Curr. Med. Res. Opin (2008) [Pubmed]
  10. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Miller, P.D. Curr. Med. Res. Opin (2008) [Pubmed]
  11. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. Miller, P.D., Delmas, P.D., Lindsay, R., Watts, N.B., Luckey, M., Adachi, J., Saag, K., Greenspan, S.L., Seeman, E., Boonen, S., Meeves, S., Lang, T.F., Bilezikian, J.P. J. Clin. Endocrinol. Metab. (2008) [Pubmed]
  12. Anti-resorptives in the management of osteoporosis. Miller, P.D. Best Pract. Res. Clin. Endocrinol. Metab. (2008) [Pubmed]
  13. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. Miller, P.D., Chines, A.A., Christiansen, C., Hoeck, H.C., Kendler, D.L., Lewiecki, E.M., Woodson, G., Levine, A.B., Constantine, G., Delmas, P.D. J. Bone Miner. Res. (2008) [Pubmed]
  14. The role of bone biopsy in patients with chronic renal failure. Miller, P.D. Clinical J. American Society Nephrology : Cjasn (2008) [Pubmed]
  15. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. Miller, P.D., Bilezikian, J.P., Diaz-Curiel, M., Chen, P., Marin, F., Krege, J.H., Wong, M., Marcus, R. J. Clin. Endocrinol. Metab. (2007) [Pubmed]
  16. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Miller, P.D., Schwartz, E.N., Chen, P., Misurski, D.A., Krege, J.H. Osteoporos. Int (2007) [Pubmed]
  17. Monitoring osteoporosis therapies. Miller, P.D. Curr. Osteoporos. Rep (2007) [Pubmed]
  18. Is there a role for bisphosphonates in chronic kidney disease?. Miller, P.D. Semin. Dial (2007) [Pubmed]
  19. Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study. Miller, P.D., Silverman, S.L., Gold, D.T., Taylor, K.A., Chen, P., Wagman, R.B. Osteoporos. Int (2006) [Pubmed]
  20. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Miller, P.D. Rev. Endocr. Metab. Disord (2006) [Pubmed]
  21. Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists. Miller, P.D. Curr. Rheumatol. Rep (2005) [Pubmed]
  22. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Miller, P.D. Clin. Ther (2005) [Pubmed]
  23. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Miller, P.D., McClung, M.R., Macovei, L., Stakkestad, J.A., Luckey, M., Bonvoisin, B., Reginster, J.Y., Recker, R.R., Hughes, C., Lewiecki, E.M., Felsenberg, D., Delmas, P.D., Kendler, D.L., Bolognese, M.A., Mairon, N., Cooper, C. J. Bone Miner. Res. (2005) [Pubmed]
  24. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Miller, P.D. Curr. Osteoporos. Rep (2005) [Pubmed]
  25. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. Miller, P.D., Shergy, W.J., Body, J.J., Chen, P., Rohe, M.E., Krege, J.H. J. Rheumatol. (2005) [Pubmed]
  26. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Miller, P.D. Curr. Osteoporos. Rep (2005) [Pubmed]
  27. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. Miller, P.D., Roux, C., Boonen, S., Barton, I.P., Dunlap, L.E., Burgio, D.E. J. Bone Miner. Res. (2005) [Pubmed]
  28. Pitfalls in bone mineral density measurements. Miller, P.D. Curr. Osteoporos. Rep (2004) [Pubmed]
  29. Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis. Miller, P. South. Med. J. (2003) [Pubmed]
  30. Bone mass measurements. Miller, P.D. Clin. Geriatr. Med. (2003) [Pubmed]
  31. Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis. Miller, P.D. Expert. Opin. Pharmacother (2003) [Pubmed]
  32. Bisphosphonates for the prevention and treatment of corticosteroid-induced osteoporosis. Miller, P.D. Osteoporos. Int (2001) [Pubmed]
  33. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. Miller, P.D., Baran, D.T., Bilezikian, J.P., Greenspan, S.L., Lindsay, R., Riggs, B.L., Watts, N.B. J. Clin. Densitom (1999) [Pubmed]
  34. The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements?. Miller, P.D., Bonnick, S.L., Johnston, C.C., Kleerekoper, M., Lindsay, R.L., Sherwood, L.M., Siris, E.S. J. Clin. Densitom (1998) [Pubmed]
 
WikiGenes - Universities